## Comparative Evaluation of SARS-CoV-2 IgG Assays in India

DBT India Consortium for Covid-19 Research\*

\*The members of the consortium and the writing committee are listed at the end of the article.

## Corresponding author:

Professor Shinjini Bhatnagar,

Translational Health Science and Technology Institute,

(Autonomous institute of the Dept of Biotechnology, Govt of India)

NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurugram Expressway,

PO box #04, Faridabad - 121001 (Haryana), India

Shinjini.bhatnagar@thsti.res.in

Word count - abstract: 157

Word count - text: 2405

All rights reserved. No reuse allowed without permission.

**Abstract:** 

IgG immunoassays have been developed and used widely for clinical samples and

serosurveys for SARS-CoV-2. We compared the performance of three

immunoassays, an in-house RBD assay, and two commercial assays, the Diasorin

LIAISON SARS-CoV-2 IgG CLIA which detects antibodies against S1/S2 domains of

the Spike protein and the Zydus Kavach assay based on inactivated virus using a

well-characterized sera-panel. 379 sera/plasma samples from RT-PCR positive

individuals >20 days of illness in symptomatic or RT-PCR positivity in asymptomatic

individuals and 184 pre-pandemic samples were used. The sensitivity of the assays

were 84.7, 82.6 and 75.7 respectively for RBD, LIAISON and Kavach. Kavach and

the in-house RBD ELISA showed a specificity of 99.5% and 100%, respectively. The

**RBD** showed and LIAISON (S1/S2) assays high agreement

(94.7%;95%CI:92.0,96.6) and were able to correctly identify more positives than

Kavach. All three assays are suitable for serosurveillance studies, but in low

prevalence sites, estimation of exposure may require adjustment based on our

findings.

**Keywords:** SARS-CoV-2, Covid-19, seroconversion, IgG, Immunoassay, sensitivity,

specificity, LIAISON SARS-CoV-2 S1/S1 IgG, Zydus Kavach, RBD IgG ELISA

Abbreviations: RBD - Receptor Binding Domain, CLIA - Chemi-Luminescence

Immuno Assay, ELISA: Enzyme Linked ImmunoSorbent Assay, MHRA – The UK

Medicines and Healthcare products Regulatory Agency

#### 1 Introduction

- 2 Nucleic acid-based diagnostic tests like RT-PCR have shown considerable sensitivity
- and specificity for detection of active SARS-CoV-2 infections and are being used as the
- 4 primary diagnostic tool. Serological tests, on the other hand, are important tools for
- 5 estimation of seroprevalence of the disease at a community level. At an individual level,
- 6 serological evidence may be a correlate of exposure or vaccine response.
- 7 Performance characteristics of serological tests determine their utility and interpretation of results. For SARS-CoV2, many tests have been developed but there are limited 8 direct comparisons. Approximately 390 tests for IgG, IgM, IgA and total antibody have 9 been developed across a range of platforms including chemiluminescence, magnetic 10 11 bead-based assays, microwell ELISA, lateral flow, etc. using different portions of the spike and nucleocapsid proteins as well as whole inactivated virus [1]. Although the 12 nucleocapsid is more abundant and immunogenic, most assays in use or in 13 14 development have utilized different regions of the spike protein or whole virus as the capture reagent in immunoassays. This is mainly because anti- spike antibodies are 15 believed to be less cross-reactive based on viral spike homology and are expected to 16 correlate better with neutralizing capacity of convalescent sera. Most of these assays 17 have been developed rapidly, many under emergency use authorization, and hence 18 were evaluated by the developers in a limited set of samples. The performance of these 19 assays in larger sample sets in various real-world setting is necessary to interpret the 20 results of the seroepidemiological studies conducted using these assays. 21

22 In this study, we evaluate three serological tests, one in-house ELISA, a commercial ELISA, and a commercial chemiluminescence immunoassay and report their sensitivity based on 379 RT-PCR positive convalescent sera and plasma samples collected from a prospective cohort of COVID-19 positive participants and specificity based on 184 prepandemic participants. We also perform head-to-head analyses of their ability to correctly identify IgG positive samples.

#### **Materials and Methods**

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

## Participants for serological assay comparison

The participants for this study were derived from a longitudinal cohort of COVID-19 positive participants known as the Department of Biotechnology India COVID-19 Consortium cohort, with ongoing recruitment from March 2020 at eight clinical sites in the Delhi- National Capital Region, India. The participants in this cohort are derived from two types of enrollment: i) Suspected COVID-19 patients enrolled at the time of RT-PCR testing at the screening center and ii) RT-PCR confirmed COVID-19 positive patients admitted at one of the clinical sites. The testing by RT-PCR was done at an approved laboratory as per the National Testing Strategy of India [2]. The RT-PCR confirmed COVID-19 patients were followed up at 10-28 days and 6-8 weeks of onset of illness. During the enrollment and follow-up detailed clinical information on the exposure history, clinical features and comorbidities were documented. Venous blood samples are collected, transported, processed and stored per protocol [3]. All enrollments were made after an informed consent process and the study protocol was approved by the Institute Ethics Committees of the participating research institutes and hospitals.

The COVID-19 positive reference standard sera panel (n=379) was formed using the sera/plasma samples collected ≥20 days of illness or following RT-PCR positivity. This criterion is in alignment with the UK Medicines and Healthcare products Regulatory Agency (MHRA) to improve comparability [4,5]. The duration of illness for asymptomatic participants was calculated from their date of diagnosis. For symptomatic participants, it was calculated from the date of testing or date of onset of symptoms whichever was the earlier. The COVID-19 negative standard panel was built from sera samples collected in the pre-pandemic period (184 from pregnant women enrolled in a pregnancy cohort) to ensure a clean set of negative samples[4–6].

#### Index test methods and alternate reference tests

54 Index test: THSTI In-house RBD IgG ELISA

SARS-CoV-2 RBD protein was diluted to 2µg/ml in PBS pH 7.4 and 50 µl/well was coated on maxisorp polystyrene plate (Thermo Scientific). Plates were incubated at 4 °C for overnight. Next day, the wells were washed 3 times with PBST (PBS with 0.1% Tween 20) using 96-well plate-washer (Tecan AG). Two hundred microliter of blocking solution (PBST with 3% skim milk) was added to all the wells. The Plates were incubated at 20°C for 2 hours. After 2 hours of incubation, plates were removed from the incubator and the blocking solution was thrown off. Hundred microliter of diluted test serum or control samples (1:50 dilution in PBST with 1% skim milk) were added to the appropriate wells and the plates were incubated at 20°C. After 2 hours of incubation, plates were removed from the incubator and washed 3 times with PBST. Horse Radish Peroxidase labeled goat anti-Human IgG Fcy-sp. Tracer antibody (Jackson Immuno

Research, Pennsylvania, USA) was diluted 1:5000 in PBST with 1% skim milk and 50  $\mu$ l of diluted tracer was added in each well of the plates. Plates were incubated in a 20°C incubator for 1 hour. After the completion of the incubation period, plates were washed 3 times with PBST and in each well 100 $\mu$ l of TMB substrate (BD Biosciences) was added and plates were incubated at room temperature for 10 min in dark. Fifty microliter of stop solution (1M  $H_2SO_4$ ) was added in each well and the absorbance was measured using a microplate reader (Biorad, California, USA) at 450 nm with 650 nm as reference wavelength. In each assay, 8 known negative samples with variable background were used as control to calculate the cut-off value. The cut-off value was calculated using the formula: Cut-off = Average OD value of negative control samples + 3\* SD of OD value of negative control samples

## 77 Covid Kavach IgG ELISA

Covid Kavach IgG ELISA was developed by the Indian Council of Medical Research's National Institute of Virology, and manufactured by Zydus [7]. The test was performed as per manufacturer's instructions. The kit suggests interpretation of the results by a two-pronged method, based on OD value and P/N (Positive/Negative Ratio). When both read-outs are in agreement, then the sample is considered positive or negative. The manufacturer's instruction does not mention interpretation for samples with a read-out not in agreement for the two criteria. We considered such results negative.

#### DiaSorin CLIA

The LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescence assay manufactured by
DiaSorin was also used for comparison. This test uses S1/S2 antigens to capture

specific IgG antibodies. The test was performed as per manufacturer's instructions, with calibration and positive and negative controls run before each batch of antibody testing as per manufacturer's protocol [8]. The tests were considered positive when the IgG concentration was ≥15 AU/mL, negative when the concentration was <12 AU/mL and equivocal when the concentration was >12 and <15 AU/mL. Equivocal samples were considered negative for sensitivity analysis.

#### Statistical analysis

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

In the absence of a gold standard for SARS-CoV-2 IgG immunoassays, an alternate reference standard was used for this study, which is SARS-COV-2 RT-PCR positivity with >20 days duration of illness (symptomatic) or >20 days beyond RT-PCR positivity (asymptomatic). While comparing the three assays, we report sensitivity and specificity of each test with the positive and negative reference standards as defined. In addition, we performed a head-to-head analysis for agreement between these methods. We estimated the global agreement calculated as the sum of the number of positives by both methods and number negative by both divided by the total number of samples. We estimated the bias index defined as the difference in the proportion of positivity for any bias between the methods to check whether one method was superior to the other in correctly identifying positive samples. As the prevalence of positives and negatives may play a role in the interpretation of the kappa statistic, we report the prevalence index defined as difference between probability of positives and probability of negatives. We finally report the kappa statistic adjusted for prevalence and bias known as prevalence and bias-adjusted kappa [9]. We then compared the sensitivity of the three candidate tests across different periods of illness. All analyses were done using the STATA-SE-15

software (Texas, USA) and the Kappa coefficient and related indices were estimated using Cohenkap package for STATA [10].

#### Results

Samples defined by an Alternate Reference Standard used for comparative evaluation

The reference true positive sample panel consisted of 379 samples from 368 participants; 11 of whom provided two samples at different time-points. The distribution of the duration of illness was bimodal owing to the design of the cohort from which the samples were derived. The means of the sampling window distributions are 23.5 and 49.3 days respectively (Supplementary figure 2). Most samples (83.7%) were obtained from symptomatic individuals. Nearly half of the samples were sera, rest were plasma. The reference negative panel consisted of 184 pre-pandemic samples collected before September 2019.

#### Comparison of the sensitivity and specificity of candidate assays

Among the three candidate tests, RBD IgG ELISA demonstrated the highest sensitivity (84.7; 95%CI: 80.6 - 88.1) and Zydus Kavach the least (75.7; 95%CI: 71.0 - 79.9). Zydus Kavach is interpreted as positive when both test parameters were positive based on cut-Off and P/N ratio. Six samples were indeterminate in Zydus Kavach test; and 25 samples were positive only by one condition (Cut-off, P/N ratio) by Zydus Kavach. Seven samples were reported as indeterminate by DiaSorin CLIA. When Zydus Kavach was interpreted as positive with one of the two criteria, 25 additional samples were identified as positive, improving the sensitivity to 81.8%. The sensitivities of the tests did not change with the increase in the duration of illness beyond 20 days (Supplementary

table 5). The specificities of Zydus Kavach and RBD ELISA were 99.5 and 100% respectively (Table-1, Figure-1). The specificity of DiaSorin could not be evaluated due to limited availability of pre-pandemic negative sera.

Tests	Sensitivity (95%CI)	Specificity
Zydus-Kavach	75.7 (71.0 - 79.9)	99.5%
DiaSorin CLIA	82.6 (78.3 - 86.2)	
RBD ELISA	84.7 (80.6 - 88.1)	100%

## Table 1: Sensitivity (%) and specificity (%) of Zydus-Kavach, DiaSorin CLIA & THSTI-RBD ELISA

- Total true positive samples evaluated: 379; true negative samples: 184
- The specificity of DiaSorin could not be evaluated due to limited availability of pre-
- pandemic negative sera.




Figure 1. Plot of sensitivity (95% confidence intervals) for the candidate assays

The dots represent the sensitivity (%) and the bars, 95% CI.

## Comparison of Zydus-Kavach, DiaSorin CLIA & RBD ELISA

When evaluated for agreement between the tests, DiaSorin CLIA and RBD ELISA had highest concordance with a global agreement 0f 94.7% (95%CI: 92.0, 96.6). There was minimal bias between the two tests; with just 6 samples positive with DiaSorin labelled negative by RBD ELISA. Among the other 14 discordant samples that were positive by RBD ELISA, five were equivocal by DiaSorin and the rest were negative. The agreement estimated by prevalence and bias-adjusted kappa statistic (0.89) was near perfect between the two tests (Table-2 & Supplementary table-4).

On the other hand, head-to-head comparison of DiaSorin CLIA and RBD ELISA against Zydus Kavach demonstrated that the degrees of agreement were modest. The global agreement between the pairs of DiaSorin CLIA and Zydus Kavach, and RBD ELISA and Zydus Kavach were 88.7% (95%CI: 85.1, 91.5) and 87.3% (95%CI: 83.6, 90.3) respectively (Table-2). DiaSorin CLIA and RBD ELISA were superior to Zydus Kavach ELISA and were able to correctly identify 7% and 9% more IgG positive sera than the latter (Supplementary tables 2 & 3).

Kit	Zydus-Kavach	DiaSorin CLIA	RBD ELISA
Zydus-Kavach		88.7% (95%CI: 85.1, 91.5)	87.3% (95%CI: 83.6, 90.3)
DiaSorin CLIA	0.77		94.7% (95%CI: 92.0, 96.6)
RBD ELISA	0.75	0.89	

Table 2: Head-to-head comparison of Zydus-Kavach, DiaSorin CLIA & RBD ELISA

Numbers in the cells below the diagonal in the table denote Prevalence and Bias adjusted Kappa statistic. Numbers in the cells above the diagonal in the table denote agreement and 95%CI calculated as (positive by both methods + negative by both)/ total samples

#### **Discussion**

Comparison of three assays on a well-characterized sample set showed that the DiaSorin CLIA and the in-house RBD ELISA performed slightly better than the Zydus Kavach ELISA with higher sensitivity and ability to identify more IgG positive samples. These results are important as they help interpretation of the serosurveillance studies that are being conducted in India using these tests.

The sensitivities reported in our study are less than reported by the companies or elsewhere [5,7]. An independent evaluation of DiaSorin CLIA, the sensitivity was reported to be 95.0% (95%CI: 92.8, 96.7), which is at least 13 percentage points higher than this report [3]. While unlikely, this difference could be attributed to false positives in our RT-PCR assay since we used RT-PCR positive convalescent samples as reference standards. Similarly, the article reporting internal validation of Zydus Kavach ELISA reported a sensitivity of 92.37% based on samples that were positive in a microneutralization assay as against 75.7% that we see in our study using sera collected >20 days post-RT-PCR positivity [7]. While we harmonised our definition of positive reference standard with that of the UK MHRA, about 14% of our participants were asymptomatic, and may have had a lower antibody response as reported in a longitudinal study, albeit with small numbers, which showed that 2/24 of their participants did not seroconvert when followed up 20-28 days into their illness [11].

To overcome the limitation of an imperfect positive reference standard and to improve inferences, the relative performance of these tests was evaluated by head-to-head comparison. RBD ELISA and DiaSorin CLIA were able to identify more positive IgG

sera/plasma than Zydus Kavach. However, RBD ELISA is an in-house ELISA developed using similar sample collections. While the sample panel used for evaluation was independent of that used in the development of the RBD ELISA, its true test would be when it is evaluated externally.

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

Highly sensitive serological assays can assess immune response to SARS-CoV-2 and are needed to determine the extent of spread of the virus, which in turn is critical for assessing case fatality rates and herd immunity. Serological assays also help in assessing development of herd immunity to devise community management strategies that are of crucial importance at this time, and will continue to be relevant in the coming years. Other uses of serological assays can be to assess exposure in high-risk populations such as healthcare workers and assess vaccination strategy at state or national level. Cross-reactivity with SARS-CoV and seasonal coronaviruses in different population and timing of IgM and IgG responses need to continue to be considered. Till date, studies on comparative performance serological assays for SARS-CoV-2 show a range of sensitivity of 84-98% and specificity of 96-99% [12-29]. Two of the three IgG assays in this study used the Spike protein (Receptor binding domain or RBD in THSTI-In-house ELISA and S1/S2 in DiaSorin CLIA), while the specific antigenic epitope(s) of the inactivated virus in the Kavach assay are not defined. Since RBD in the spike protein is the major site of ACE-2 binding, assays with this target may have more concordance with neutralizing antibodies. The spike protein has more CD4 and CD8 T cell immunodominant epitopes as experimentally shown in SARS-CoV, and since these epitopes are mostly conserved even in SARS-CoV-2 isolates, serological assays

targeting RBD or full length S1/S2 are putatively more appropriate for assessing longterm immune status [30].

## **Conclusion:**

Overall, this is the first comparative study of SARS-CoV-2 IgG assays in India evaluated independently against a strategically designated alternate reference standard. One limitation of this study is that we were unable to evaluate the specificity of the Diasorin assay due to paucity of negative samples. Nonetheless, the well characterized panels provide useful information for decision-making for choice of serological assays.

221	Ref	erences
222	[1]	SARS-CoV-2 diagnostic pipeline, FIND. <a href="https://www.finddx.org/covid-19/pipeline/">https://www.finddx.org/covid-19/pipeline/</a>
223		(accessed August 8, 2020).
224	[2]	Strategy for COVID-19 testing in
225		India. https://www.icmr.gov.in/pdf/covid/strategy/Testing_Strategy_v5_18052020.p
226		df (accessed August 7, 2020)
227	[3]	SOP_Specimen_Collection_2019-
228		nCoV.pdf. https://niv.co.in/SOP_Specimen_Collection_2019-nCoV.pdf (accessed
229		August 7, 2020).
230	[4]	Target Product Profile: enzyme Immunoassay (EIA) Antibody tests to help
231		determine if people have antibodies to SARS-CoV-2,
232		GOV.UK. https://www.gov.uk/government/publications/how-tests-and-testing-kits-
233		for-coronavirus-covid-19-work/target-product-profile-enzyme-immunoassay-eia-
234		antibody-tests-to-help-determine-if-people-have-antibodies-to-sars-cov-2
235		(accessed August 7, 2020).
236	[5]	Public Health England Porton Down, Evaluation of sensitivity and specificity of four
237		commercially available SARS-CoV-2 antibody immunoassays, Public Health
238		England, Porton Down Nuffield Department of Medicine, University of Oxford
239		Oxford University Hospitals NHS Foundation
240		Trust, <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads">https://assets.publishing.service.gov.uk/government/uploads/system/uploads</a>
241		/attachment_data/file/898437/Evaluationof_sensitivity_and_specificity_of_4_com
242		mercially_available_SARS-CoV-2_antibody_immunoassays.pdf (accessed August
243		7, 2020).

244 [6] S. Bhatnagar, P.P. Majumder, D.M. Salunke, Interdisciplinary Group for Advanced Research on Birth Outcomes—DBT India Initiative (GARBH-Ini), A Pregnancy 245 Cohort to Study Multidimensional Correlates of Preterm Birth in India: Study 246 Design, Implementation, and Baseline Characteristics of the Participants, American 247 Journal of Epidemiology. 188 (2019) 621-631. https://doi.org/10.1093/aje/kwy284. 248 [7] G. Sapkal, A. Shete-Aich, R. Jain, P.D. Yadav, P. Sarkale, R. Lakra, S. Baradkar, 249 G.R. Deshpande, D. Mali, B.N. Tilekar, T. Majumdar, H. Kaushal, Y. Gurav, N. 250 Gupta, S. Mohandas, K. Deshpande, O. Kaduskar, M. Salve, S. Patil, S. Gaikwad, 251 A.P. Sugunan, M. Ashok, S. Giri, J. Shastri, P. Abraham, R.R. Gangakhedkar, C.S. 252 Team, Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-253 2 IgG, Indian Journal of Medical Research. 151 (2020) 254 444. https://doi.org/10.4103/ijmr.IJMR\_2232\_20. 255 [8] LIAISON® SARS-CoV-2 S1/S2 256 IgG https://www.diasorin.com/sites/default/files/allegati prodotti/liaison sars-cov-257 2 s1 s2 igg 0.pdf (accessed August 7, 2020). 258 [9] T. Byrt, J. Bishop, J.B. Carlin, Bias, prevalence and kappa, Journal of Clinical 259 Epidemiology. 46 (1993) 423–429. https://doi.org/10.1016/0895-4356(93)90018-V . 260 [10] Cohenkap package for STATA software for agreement 261 analysis. <a href="http://www.graunt.cat/stata/cohenkap.ado">http://www.graunt.cat/stata/cohenkap.ado</a> (accessed August 7, 2020). 262 263 [11] M. Chatzidimitriou, F. Chatzopoulou, E. Gavriilaki, P. Chatzivasileiou, D. Rousis, G. Meletis, D. Chatzidimitriou, Repeated negative serological testing in otherwise 264 healthy patients with COVID-19, The Journal of Infectious Diseases. 265

(2020). https://doi.org/10.1093/infdis/jiaa453.

- [12] M.L. Bastos, G. Tavaziva, S.K. Abidi, J.R. Campbell, L.-P. Haraoui, J.C. Johnston,
- Z. Lan, S. Law, E. MacLean, A. Trajman, D. Menzies, A. Benedetti, F.A. Khan,
- Diagnostic accuracy of serological tests for covid-19: systematic review and meta-
- analysis, BMJ. 370 (2020). <a href="https://doi.org/10.1136/bmj.m2516">https://doi.org/10.1136/bmj.m2516</a> .
- [13] M.K. Das, A. Chaudhary, A. Bryan, M.H. Wener, S.L. Fink, C. Morishima, Rapid
- Screening Evaluation of SARS-CoV-2 IgG Assays Using Z-Scores to Standardize
- 273 Results, (n.d.). <a href="https://doi.org/10.3201/eid2610.202632">https://doi.org/10.3201/eid2610.202632</a> .
- [14] C.L. Charlton, J.N. Kanji, K. Johal, A. Bailey, S.S. Plitt, C. MacDonald, A. Kunst, E.
- Buss, L.E. Burnes, K. Fonseca, B.M. Berenger, K. Schnabl, J. Hu, W. Stokes, N.
- Zelyas, G. Tipples, Evaluation of six commercial mid to high volume antibody and
- six point of care lateral flow assays for detection of SARS-CoV-2 antibodies,
- Journal of Clinical Microbiology. (2020). https://doi.org/10.1128/JCM.01361-20.
- [15] K.G. Beavis, S.M. Matushek, A.P.F. Abeleda, C. Bethel, C. Hunt, S. Gillen, A.
- Moran, V. Tesic, Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay
- for detection of IgA and IgG antibodies, J. Clin. Virol. 129 (2020)
- 282 104468. <a href="https://doi.org/10.1016/j.jcv.2020.104468">https://doi.org/10.1016/j.jcv.2020.104468</a> .
- [16] C. Bundschuh, M. Egger, K. Wiesinger, C. Gabriel, M. Clodi, T. Mueller, B.
- Dieplinger, Evaluation of the EDI enzyme linked immunosorbent assays for the
- detection of SARS-CoV-2 IgM and IgG antibodies in human plasma, Clinica
- 286 Chimica Acta. 509 (2020) 79–82. https://doi.org/10.1016/j.cca.2020.05.047.
- [17] M. Egger, C. Bundschuh, K. Wiesinger, C. Gabriel, M. Clodi, T. Mueller, B.
- Dieplinger, Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the
- EDI<sup>TM</sup> enzyme linked immunosorbent assays for the detection of SARS-CoV-2

- 290 antibodies in human plasma, Clin. Chim. Acta. 509 (2020) 18-21. https://doi.org/10.1016/j.cca.2020.05.049. 291 [18] V. Haselmann, M. Kittel, C. Gerhards, M. Thiaucourt, R. Eichner, V. Costina, M. 292 Neumaier, Comparison of test performance of commercial anti-SARS-CoV-2 293 immunoassays in serum and plasma samples, Clin. Chim. Acta. 510 (2020) 73-294 78. https://doi.org/10.1016/j.cca.2020.07.007. 295 [19] S. Hörber, J. Soldo, L. Relker, S. Jürgens, J. Guther, S. Peter, R. Lehmann, A. 296 Peter, Evaluation of three fully-automated SARS-CoV-2 antibody assays, (n.d.) 8. 297 [20] A.J. Jääskeläinen, S. Kuivanen, E. Kekäläinen, M.J. Ahava, R. Loginov, H. Kallio-298 Kokko, O. Vapalahti, H. Jarva, S. Kurkela, M. Lappalainen, Performance of six 299 SARS-CoV-2 immunoassays in comparison with microneutralisation, J. Clin. Virol. 300 129 (2020) 104512. https://doi.org/10.1016/j.jcv.2020.104512. 301 [21] A.J. Jääskeläinen, E. Kekäläinen, H. Kallio-Kokko, L. Mannonen, E. Kortela, O. 302 Vapalahti, S. Kurkela, M. Lappalainen, Evaluation of commercial and automated 303
- Vapalahti, S. Kurkela, M. Lappalainen, Evaluation of commercial and automated

  SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient

  samples, Eurosurveillance. 25 (2020). <a href="https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000603">https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000603</a>.
- [22] J.-H. Ko, E.-J. Joo, S.-J. Park, J.Y. Baek, W.D. Kim, J. Jee, C.J. Kim, C. Jeong, Y. J. Kim, H.J. Shon, E.-S. Kang, Y.K. Choi, K.R. Peck, Neutralizing Antibody
   Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with
   Pneumonic COVID-19 Patients, J Clin Med. 9
- 311 (2020). <a href="https://doi.org/10.3390/jcm9072268">https://doi.org/10.3390/jcm9072268</a> .

- [23] A. Krüttgen, C.G. Cornelissen, M. Dreher, M. Hornef, M. Imöhl, M. Kleines,
- Comparison of four new commercial serologic assays for determination of SARS-
- 314 CoV-2 IgG, J. Clin. Virol. 128 (2020)
- 315 104394. <a href="https://doi.org/10.1016/j.jcv.2020.104394">https://doi.org/10.1016/j.jcv.2020.104394</a> .
- 316 [24] A.E. Merrill, J.B. Jackson, A. Ehlers, D. Voss, M.D. Krasowski, Head-to-Head
- Comparison of Two SARS-CoV-2 Serology Assays, The Journal of Applied
- Laboratory Medicine. (2020). <a href="https://doi.org/10.1093/jalm/jfaa125">https://doi.org/10.1093/jalm/jfaa125</a> .
- [25] B. Meyer, G. Torriani, S. Yerly, L. Mazza, A. Calame, I. Arm-Vernez, G. Zimmer, T.
- Agoritsas, J. Stirnemann, H. Spechbach, I. Guessous, S. Stringhini, J. Pugin, P.
- Roux-Lombard, L. Fontao, C.-A. Siegrist, I. Eckerle, N. Vuilleumier, L. Kaiser,
- Validation of a commercially available SARS-CoV-2 serological immunoassay,
- 323 Clinical Microbiology and Infection.
- 324 (2020). <a href="https://doi.org/10.1016/j.cmi.2020.06.024">https://doi.org/10.1016/j.cmi.2020.06.024</a> .
- [26] M.S. Tang, K.G. Hock, N.M. Logsdon, J.E. Hayes, A.M. Gronowski, N.W.
- Anderson, C.W. Farnsworth, Clinical Performance of Two SARS-CoV-2 Serologic
- 327 Assays, Clinical Chemistry. 66 (2020) 1055–
- 328 1062. <a href="https://doi.org/10.1093/clinchem/hvaa120">https://doi.org/10.1093/clinchem/hvaa120</a> .
- [27] E.S. Theel, J. Harring, H. Hilgart, D. Granger, Performance Characteristics of Four
- High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-
- 331 CoV-2, Journal of Clinical Microbiology. 58
- 332 (2020). <a href="https://doi.org/10.1128/JCM.01243-20">https://doi.org/10.1128/JCM.01243-20</a> .
- [28] L. Weidner, S. Gänsdorfer, S. Unterweger, L. Weseslindtner, C. Drexler, M. Farcet,
- V. Witt, E. Schistal, P. Schlenke, T.R. Kreil, C. Jungbauer, Quantification of SARS-

335	CoV-2 antibodies with eight commercially available immunoassays, J. Clin. Virol.
336	129 (2020) 104540. https://doi.org/10.1016/j.jcv.2020.104540.
337	[29] M. Lisboa Bastos, G. Tavaziva, S.K. Abidi, J.R. Campbell, LP. Haraoui, J.C.
338	Johnston, Z. Lan, S. Law, E. MacLean, A. Trajman, D. Menzies, A. Benedetti, F.
339	Ahmad Khan, Diagnostic accuracy of serological tests for covid-19: systematic
340	review and meta-analysis, BMJ. (2020) m2516. https://doi.org/10.1136/bmj.m2516
341	[30] M.G. Nasab, A. Saghazadeh, N. Rezaei, SARS-CoV-2-A Tough Opponent for the
342	Immune System, Arch. Med. Res.
343	(2020). https://doi.org/10.1016/j.arcmed.2020.05.020.
344	
345	

Writing committee: 346 Susmita Chaudhuri\*, Ramachandran Thiruvengadam\*, Pallavi Kshetrapal, Gaurav 347 Bapu Koundinya Desiraju, Gagandeep Kang<sup>\$</sup>, Shinjini Batra, Tripti Shrivastava, 348 Bhatnagar# 349 \*Equally contributed to the manuscript 350 \*Co-corresponding author 351 # Corresponding authors 352 353 Members of DBT India consortium for COVID-19 Research 354 Coordinating Institute: Translational Health Science and Technology Institute (THSTI) 355 Coordinating Principal Investigator: Dr Shinjini Bhatnagar 356 Co- Principal Investigator: Dr Gagandeep Kang 357 Co-Investigators (Clinical): Drs Nitya Wadhwa, Uma Chandramouli 358 Natchu, Ramachandran Thiruvengadam, Shailaja Sopory, Pallavi Kshetrapal, Bapu Koundinya 359 Desiraju, Vandita Bhartia, Mudita Gosain 360 Co-Investigators (Laboratory): Drs Gaurav Batra, Guruprasad Medigeshi, Susmita 361 Chaudhuri, Niraj Kumar, Tarun Sharma, Chandresh Sharma, Shailendra Mani, Tripti 362 Shrivastava 363 Clinical Operations Lead: Dr. Monika Bahl 364 International Centre for Genetic Engineering and Biotechnology (ICGEB): Dr Anmol 365 Chandele 366 Delhi University, South Campus, New Delhi: Dr Vijay Kumar Chaudhary 367 368 National Institute of immunology (NII): Drs. Amulya Panda, Nimesh Gupta

- Maulana Azad Medical College and Lok Nayak Jai Prakash Narayan Hospital, New
- Delhi: Drs. Nandini Sharma, Pragya Sharma, Sonal Saxena, J.C. Passey, Suresh
- 371 Kumar
- ESI Medical College and Hospital, Faridabad, Haryana: Dr Asim Das, Anil K Pandey,
- 373 Nikhil Verma
- Civil Hospital Gurugram (GCH), Haryana: Drs Deepa Sindhu, Jai Singh Malik
- 375 Civil Hospital Palwal (PCH), Haryana: Dr Brahmdeep Sindhu
- 376 Al-Falah School of Medical Science & Research Centre and Hospital, Dhouj, Haryana:
- 377 Drs S.K.S. Puri, Bhupinder Kaur Anand, Shubham Girdhar
- Medanta Hospital, Gurugram, Haryana: Drs Sushila Kataria, Pooja Sharma
- 379 Shaheed Hasan Khan Mewati Government Medical College, Nalhar, Nuh, Haryana: Dr
- 380 Yamini

385

- Lady Hardinge Medical College, New Delhi: Drs. Harish K. Pemde, Tanmaya Talukdar
- SGT Medical college, Gurugram, Haryana: Drs. Pankaj Abrol, Mukesh Sharma
- Dr. Dang's Lab, New Delhi: Drs Navin Dang, Manavi Dang, Arjun Dang, Leena
- 384 Chatterjee, Devjani De

#### Author contribution:

- SB, GK, SC and RT conceptualized the study; All members of DBT India consortium for
- 387 COVID-19 Research devised methods, collected samples and clinical data; SC, GB,
- TS, PK, ND, MD, AD, LC and DD provided reagents and analysed samples; RT, SC
- and BKD curated and analysed data; SC, RT and GK drafted the manuscript; GK and
- 390 SB coordinated and supervised the study. All authors contributed in revision and
- approved the final draft of the manuscript.

## **Acknowledgement:**

We deeply thank the Department of Biotechnology, Government of India for supporting the consortium. We are grateful to the leadership and administration of all partner institutions in the consortium for their help and support. We thank all the clinical, laboratory and data management staff for their contributions to this work and the consortium at large.

Declarations of interest: none

## Supplementary material

399

400

## sTable 1: Head-head comparison of Zydus-Kavach & DiaSorin CLIA:

	Zydus-Kavach	Zydus-Kavach	
	Positive	Negative	
DiaSorin CLIA Positive	278	34	312
DiaSorin CLIA Negative	9	58	67
	287	92	379

## 401 Agreement/concordance analysis

402 Global agreement: 88.7% (95%Cl: 85.1, 91.5)

Specific agreement for positivity: 92.8% (95%CI: 90.5, 94.6)

Specific agreement for negativity: 73.0% (95%CI: 65.6, 79.3)

Cohen's Kappa statistic: 0.66 (95%CI: 0.57, 0.75)

#### **Observed disagreement:**

407 DiaSorin+Kavach-: 8.97% Kavach+DiaSorin-: 2.37%

Bias index (Difference in the proportion of positivity)= 0.07

DiaSorin is able to identify more cases than Zydus Kavach

Prevalence index: 0.58

Prevalence and Bias-adjusted Kappa (PABAK): 0.77 (Inference: Substantial

412 agreement)

413

404

405

406

408

409

410

411

## sTable 2: Head-head comparison of Zydus-Kavach & RBD ELISA:

	Zydus-Kavach	Zydus-Kavach	
	Positive	Negative	
RBD ELISA positive	280	41	321
RBD ELISA Negative	7	51	58
	287	92	379

## 416 Agreement/concordance analysis

- 417 Global agreement: 87.3% (95%CI: 83.6, 90.3)
- Specific agreement for positivity: 92.1% (95%CI: 89.7, 94.0)
- Specific agreement for negativity: 68.0% (95%CI: 60.2, 74.9)
- 420 Cohen's Kappa statistic: 0.61 (95%CI: 0.51, 0.70)

#### 421 **Observed disagreement:**

- 422 RBD ELISA+Kavach-: 10.8% Kavach+RBD ELISA: 1.9%
- Bias index (Difference in the proportion of positivity)= 0.09
- RBD ELISA is able to identify more cases than Zydus Kavach
- 425 Prevalence index: 0.60
- 426 Prevalence and Bias-adjusted Kappa (PABAK): 0.75 (Inference: Substantial
- 427 agreement)

428

429

## sTable 3: Head-head comparison of DiaSorin & RBD ELISA:

	DiaSorin Positive	DiaSorin Negative	
RBD ELISA positive	307	14	321
RBD ELISA negative	6	52	58
	313	66	379

## 431 Agreement/concordance analysis

432 Global agreement: 94.7% (95%CI: 92.0, 96.6)

Specific agreement for positivity: 96.8% (95%CI: 95.2, 97.9)

Specific agreement for negativity: 83.9% (95%CI: 76.4, 89.3)

Cohen's Kappa statistic: 0.81 (95%CI: 0.73, 0.89)

#### Observed disagreement:

437 RBD ELISA+DiaSorin-: 3.7% DiaSorin+RBD ELISA: 1.6%

Bias index (Difference in the proportion of positivity)= 0.02

Minimal bias between the RBD ELISA and DiaSorin

440 Prevalence index: 0.67

Prevalence and Bias-adjusted Kappa (PABAK): 0.89 (Inference: Almost perfect

442 agreement)

443

430

433

434

435

436

438

439

441

# sTable 4: Sensitivity of Zydus Kavach, DiaSorin, RBD ELISA across various periods of illness

Duration of illness (days)	N	Zydus Kavach		DiaSorin CLIA		RBD ELISA	
		n	Sensitivity (%)	n	Sensitivity (%)	n	Sensitivity (%)
20-30	193	145	75.1	163	84.5	167	86.5
31-40	6	6	100	6	100	5	83.3
41-50	116	83	71.6	89	76.7	92	79.3
51-60	56	48	85.7	50	89.3	51	91.1
61-72	4	2	50	2	50	3	75.0

sFigure 1: Number of samples over a range of duration of illness

